University of Heidelberg, Mannheim University Medical Center, Sarcoma Unit, Mannheim, Germany.
Department of Medical Oncology, Santo Stefano Hospital, Prato, Italy.
Eur J Surg Oncol. 2023 Jun;49(6):1133-1139. doi: 10.1016/j.ejso.2021.12.465. Epub 2021 Dec 31.
Retroperitoneal soft tissue sarcomas mainly consist histologically of liposarcomas and leiomyosarcomas. For the liposarcoma subgroup, the local relapse rate seems to determine patients' overall prognosis. In contrast, leiomyosarcoma patients are challenged by the development of metastatic disease; therefore, effective systemic therapies are the cornerstone to improve patients' outcome. No doubt, the limited number of active regimens currently available makes the treatment of patients with locally advanced and/or metastatic disease challenging and results in the overall poor prognosis of this population. In this European Journal of Surgical Oncology Educational Special Issue from the Transatlantic Australasian RetroPeritoneal Sarcoma Working Group (TARPSWG), we aim to summarize state-of-the-art systemic treatments for patients with retroperitoneal sarcomas with a focus on the locally advanced and metastatic disease setting including conventional standard chemotherapies as well as new innovative treatment approaches in order to identify current unmet medical needs guiding the sarcoma community to initiate appropriate translational research projects and design innovative clinical trials.
腹膜后软组织肉瘤主要由脂肪肉瘤和平滑肌肉瘤组织学组成。对于脂肪肉瘤亚组，局部复发率似乎决定了患者的总体预后。相比之下，平滑肌肉瘤患者面临转移性疾病的发展；因此，有效的全身治疗是改善患者预后的基石。毫无疑问，目前可用的有效方案数量有限，使得局部晚期和/或转移性疾病患者的治疗具有挑战性，并导致该人群的总体预后较差。在本期《欧洲外科肿瘤学会教育专刊》中，来自跨大西洋澳大拉西亚腹膜后肉瘤工作组（TARPSWG）的专家们旨在总结腹膜后肉瘤患者的最新系统治疗方法，重点关注局部晚期和转移性疾病的治疗，包括常规标准化疗以及新的创新治疗方法，以确定当前未满足的医疗需求，指导肉瘤界开展适当的转化研究项目和设计创新临床试验。
